DNA minor groove binders as potential antitumor and antimicrobial agents

✍ Scribed by Pier Giovanni Baraldi; Andrea Bovero; Francesca Fruttarolo; Delia Preti; Mojgan Aghazadeh Tabrizi; Maria Giovanna Pavani; Romeo Romagnoli

• Book ID: 102946247
• Publisher: John Wiley and Sons
• Year: 2004
• Tongue: English
• Weight: 597 KB
• Volume: 24
• Category: Article
• ISSN: 0198-6325
• DOI: 10.1002/med.20000

✦ Synopsis

Abstract

DNA minor groove binders constitute an important class of derivatives in anticancer therapy. Some of these compounds form noncovalent complexes with DNA (e.g., distamycin A, Hoechst 33258, and pentamidine) while others DNA‐binding compounds (such as CC‐1065) cause cleavages in the DNA backbone. In this article, we have reviewed the minor groove binders currently in preclinical evaluation in the last years. Diarylamidines such as DAPI, berenil, and pentamidine; bis‐benzimidazoles such as Hoechst 33258; ecteinascidins, pyrrololo [2,1‐c]‐[1,4]‐benzodiazepines (PBDs), CC‐1065, and distamycins are the classes discussed in this review article. A special section has been dedicated to hybrid molecules resulted by the combination of two minor groove binders, especially for derivatives of naturally occurring antitumor agents, such as anthramycin or the alkylating unit of the antibiotic CC‐1065, and distamycin frames. © 2004 Wiley Periodicals, Inc. Med Res Rev, 24, No. 4, 475–528, 2004